Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Disease Progression

NCT07268339 2025-12-05

TRAIN

Phase 3 Not yet recruiting

328 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07260162 2025-12-03

PERSEVERANCE

Phase 1 Not yet recruiting

24 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07207824 2025-10-06

HERO

Phase 3 Not yet recruiting

182 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07198451 2025-09-30

GEM-IR-NMIBC

Phase 2/3 Not yet recruiting

320 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Recurrence

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07100184 2025-08-03

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Phase 2 Not yet recruiting

30 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

31 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07053748 2025-07-08

Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy

Not yet recruiting

30 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06982690 2025-05-21

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

Phase NA Not yet recruiting

370 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Recurrence

NCT06630871 2024-10-10

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Phase 2 Not yet recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06588179 2024-09-19

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Phase 1/2 Not yet recruiting

58 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06327932 2024-03-25

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Phase 3 Not yet recruiting

320 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06227065 2024-01-26

POLO

Phase 2 Not yet recruiting

28 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05996952 2023-08-18

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Phase 2 Not yet recruiting

77 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04167332 2019-11-18

ProCSUCaB

Not yet recruiting

630 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Recurrence, Disease Progression

Clinical Trials

Tumor Budding and T1 Substaging in Urothelial Bladder Cancer

TRAIN

PERSEVERANCE

HERO

GEM-IR-NMIBC

OHAI-NMIBC-01

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

BCG-TIME

Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

POLO

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

ProCSUCaB